A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Alopecia Areata Participants
Completed · Phase 1/Phase 2
Conditions studied: Alopecia Areata (AA)
In brief
The primary objective of the study is to evaluate the safety of IMG-007 in adults with Alopecia Areata.
Key facts
- Study ID
- NCT06060977
- Run by
- Inmagene LLC
- People needed
- 29
- Starts
- 2023-09-25
- Expected to finish
- 2025-01-14
- Last updated by the study team
- 2026-02-09
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Northwest Arkansas Clinical Trials Center, PLLC/ Hull Dermatology P.A. — Rogers, Arkansas, United States
- Torrance Clinical Research Institute Inc. — Lomita, California, United States
- Alliance Clinical Research of Tampa — Tampa, Florida, United States
- Dawes Fretzin Clinical Resarch Group, LLC — Indianapolis, Indiana, United States
- Options Research Group — West Lafayette, Indiana, United States
- Lahey Hospital & Medical Center — Burlington, Massachusetts, United States
- Great Lakes Research Group Inc. — Bay City, Michigan, United States
- Skin Cancer and Dermatology Institute — Reno, Nevada, United States
- Skin Search of Rochester, Inc. — Rochester, New York, United States
- Stride Clinical Research LLC — Sugar Land, Texas, United States
- Dermatology Specialists of Spokane — Spokane, Washington, United States
- SimcoMed Health Ltd. — Barrie, Ontario, Canada
- Skin Health — Cobourg, Ontario, Canada
- Guelph Dermatology Research — Guelph, Ontario, Canada
- Research Toronto — Toronto, Ontario, Canada
- Centre de Recherche Saint-Louis — Québec, Quebec, Canada
- Innovaderm Research Inc. — Montreal, Canada
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.